QPS and Hepregen have announced an agreement, allowing QPS to offer Hepregen’s DMPK services to their clients.
QPS has recently announced an agreement with Hepregen, which allows QPS to co-promote, market and sell Hepregen’s HepatoPacTM technology for use in DMPK studies. This marks both companies’ first partnership of this kind.
USA-based CRO, QPS, provides support to a range of clients for all stages of drug development – with their specialties including DMPK, toxicology and bioanalysis studies. Hepregen, also based in the US, provide bioengineered ‘micro-liver’ platforms – used in a range of research from pharmaceutical to environmental studies.
The agreement will allow QPS to offer “metabolite identification, profiling and clearance studies” using Hepregen’s HepatoPac technology. Zamas Lam, QPS Senior Vice President of Preclinical Development, explained the importance of this agreement, “Our ability to offer services utilizing Hepregen’s next-generation product portfolio is another demonstration of the QPS commitment to enhancing its leadership position in the ADME field, providing cutting-edge, liver-based in vitro services to the pharmaceutical and agrochemical industry.”
Chief Executive at Hepregen, Vincent Zurawski, explained how this agreement benefits his company,“QPS brings an extraordinary capability and expertise in bioanalytical technology and hepatic cell biology to our partnership and a strong commitment to a progressive vision in the growing field of hepatic sciences…. We are extremely pleased to be engaged with such a strong partner in this paradigm-shifting endeavor.”